Načítá se...
NIMG-06. KINETICS-BASED RESPONSE METRIC DISCRIMINATE IMPROVED OUTCOMES FOR PATIENTS RECEIVING BEVACIZUMAB-BASED THERAPIES
INTRODUCTION: Evaluating treatment response in glioblastoma is a difficult task for clinicians, particularly in recurrent disease. Current response metrics focus on changes in imageable tumor burden which can be ambiguously affected by anti-angiogenic therapy. In previous work, we reported the abili...
Uloženo v:
| Vydáno v: | Neuro Oncol |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6217281/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.734 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|